Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

June 8, 2018: By Jon Swedien

Cincinnati Eye Institute, with the help of Denver-based Revelstoke Capital Partners, has formed a new management services organization that will seek to acquire other ophthalmic practices around the nation, CEI announced May 24.

“Our goal, with the launch of CEI Vision Partners, is to become one of the nation’s largest and most comprehensive eye care management companies,” said CEI’s board chair, Robert Foster, MD.

CEI Vision Partners is CEI’s parent company. Founded in 1945, CEI is currently a group of more than 60 practicing ophthalmologists and optometrists that maintains 14 clinical centers and three ambulatory surgical centers.

Foster declined to say how much Revelstoke invested, the Cincinnati Business Courier reported.

CEI officials said the group has the infrastructure required to scale up to offer services to other eye care groups, even if they don’t formally merge, the Courier reported.

Revelstoke helps businesses execute acquisition growth strategies. It has raised about $1.1 billion of equity and has completed 42 acquisitions since it was formed in 2013, according to CEI.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT